Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 409306 in attenuated psychosis syndrome
2016-004973-42Phase 2Unknown
- Sponsor
- Boehringer Ingelheim
- Start
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in attenuated psychosis syndrome (APS) comparing BI 409306 with Placebo (2 arms). Primary endpoint: Time to remission from attenuated psychosis syndrome. Status: unknown.
02
Drugs
osoresnontrine
03
Conditions
attenuated psychosis syndrome (APS)
Beyond the preview
Go deeper on 2016-004973-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004973-42.